Abstract: This paper presents a $71-86 \mathrm{GHz}$ 1024QAM Direct-Carrier Phase-Modulating Transmitter (DCPM-TX), solely by using 9-bit digital-to-phase converters based on digitally-controlled ...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial programme ...

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2. The new ...

Analyst/Investor Day October 1, 2025 10:00 AM EDTCompany ParticipantsJennie Daly - CEO & Executive DirectorShaun White ...